NEW YORK, April 5, 2017 /PRNewswire/ -- The seventh trial of a Risperdal lawsuit involving allegations of gynecomastia is now underway in Pennsylvania's Philadelphia Court of Common Pleas. The case currently before a jury was filed on behalf of a Plaintiff who allegedly developed female-like breasts after he was prescribed Risperdal in 2002 to treat behavioral problems associated with Asperger's syndrome. The claimant was 8 years old at the time, and Risperdal had yet to be approved for any pediatric indications. The lawsuit asserts that the Plaintiff's mother would never have agreed to his treatment had doctors been furnished with adequate warnings regarding the association between Risperdal and gynecomastia. (Case No. 130600861)
According to court documents, this is the second time a jury has been empaneled to hear this Risperdal lawsuit. A mistrial was declared last Monday, after an expert witness testifying for the Plaintiff rendered aid to a member of the previous jury who had experienced a medical emergency.
"So far, four of six Risperdal trials have resulted in financial damage awards for gynecomastia plaintiffs in Pennsylvania. Our Firm is representing numerous individuals who are alleged to have experienced similar complications after taking this medication, and we are monitoring this trial closely," said Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm continues to provide free legal reviews to individuals who may have experienced excessive male breast growth due to their use of Risperdal.
Risperdal and Male Breast Growth
Risperdal is an atypical antipsychotic approved to treat schizophrenia and other psychiatric disorders. The drug was not approved for use in children until 2006, though it has been on the market since the mid-1990s. More than 5,500 Risperdal lawsuits are pending in the Pennsylvania mass tort program, most of which involve the drug's alleged propensity to cause gynecomastia in men and boys. (In Re: Risperdal Litigation, Case ID: 100300296)
Johnson & Johnson recently acknowledged that more than 18,000 product liability claims had been filed over injuries and complications allegedly related to Risperdal.
Over the past two years, six trials involving Risperdal and male breast growth have concluded in Pennsylvania. Four have resulted in verdicts for plaintiffs, with judgments ranging from $500,000 to $70 million. Confidential Risperdal settlements have also been reached in some cases just prior to trial.
Bernstein Liebhard LLP continues to provide free legal reviews to alleged victims of Risperdal and gynecomastia. To learn more about filing a Risperdal lawsuit, please contact Bernstein Liebhard LLP by visiting the Firm's website, or by calling 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2017 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/risperdal-lawsuit-news-seventh-gynecomastia-trial-now-underway-in-pennsylvania-mass-tort-program-bernstein-liebhard-llp-reports-300435296.html
SOURCE Bernstein Liebhard LLP